Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Symkevi and Kaftrio in children with cystic fibrosis
NL-OMON52206Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tezacaftor + ivacaftor, elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Amsterdam University Medical Center. Primary endpoint: Exposure of elexacaftor, tezacaftor and ivacaftor. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
tezacaftor + ivacaftorelexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON52206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52206.